Beam Therapeutics Inc (BEAM)
22.74
-0.73
(-3.11%)
USD |
NASDAQ |
Apr 24, 16:00
22.74
0.00 (0.00%)
After-Hours: 20:00
Beam Therapeutics Enterprise Value: 667.02M for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 667.02M |
| April 23, 2024 | 726.63M |
| April 22, 2024 | 778.07M |
| April 19, 2024 | 761.74M |
| April 18, 2024 | 795.22M |
| April 17, 2024 | 795.22M |
| April 16, 2024 | 908.73M |
| April 15, 2024 | 908.73M |
| April 12, 2024 | 927.51M |
| April 11, 2024 | 1.037B |
| April 10, 2024 | 1.020B |
| April 09, 2024 | 1.204B |
| April 08, 2024 | 1.163B |
| April 05, 2024 | 1.113B |
| April 04, 2024 | 1.181B |
| April 03, 2024 | 1.234B |
| April 02, 2024 | 1.305B |
| April 01, 2024 | 1.477B |
| March 28, 2024 | 1.508B |
| March 27, 2024 | 1.583B |
| March 26, 2024 | 1.523B |
| March 25, 2024 | 1.561B |
| March 22, 2024 | 1.556B |
| March 21, 2024 | 1.664B |
| March 20, 2024 | 1.658B |
| Date | Value |
|---|---|
| March 19, 2024 | 1.655B |
| March 18, 2024 | 1.592B |
| March 15, 2024 | 1.702B |
| March 14, 2024 | 1.636B |
| March 13, 2024 | 1.862B |
| March 12, 2024 | 1.733B |
| March 11, 2024 | 1.796B |
| March 08, 2024 | 1.875B |
| March 07, 2024 | 1.828B |
| March 06, 2024 | 1.936B |
| March 05, 2024 | 1.955B |
| March 04, 2024 | 1.933B |
| March 01, 2024 | 2.063B |
| February 29, 2024 | 2.035B |
| February 28, 2024 | 2.371B |
| February 27, 2024 | 2.490B |
| February 26, 2024 | 1.733B |
| February 23, 2024 | 1.586B |
| February 22, 2024 | 1.549B |
| February 21, 2024 | 1.404B |
| February 20, 2024 | 1.407B |
| February 16, 2024 | 1.496B |
| February 15, 2024 | 1.506B |
| February 14, 2024 | 1.364B |
| February 13, 2024 | 1.257B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
388.81M
Minimum
Oct 20 2023
7.996B
Maximum
Jul 01 2021
2.540B
Average
1.793B
Median
Enterprise Value Benchmarks
| Eli Lilly and Co | 718.54B |
| Moderna Inc | 33.07B |
| Pfizer Inc | 206.77B |
| Editas Medicine Inc | 114.59M |
| Intellia Therapeutics Inc | 1.122B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 142.80M |
| Revenue (Quarterly) | 316.19M |
| Total Expenses (Quarterly) | 183.33M |
| EPS Diluted (Quarterly) | 1.73 |
| Profit Margin (Quarterly) | 45.16% |
| Earnings Yield | -8.36% |
| Normalized Earnings Yield | -8.257 |